Case Report: Hepatoid adenocarcinoma of the stomach mimicking primary ovarian cancer: long-term survival following multimodal conversion immunochemotherapy

Background Hepatoid adenocarcinoma of the stomach (HAS) is a rare, highly aggressive malignancy with no established standardized first-line treatment. Advanced HAS is typically associated with a dismal prognosis. Case presentation We report a 54-year-old female with HAS (cT3N+M1) featuring a primary lesion in the gastric body, massive ascites, and ovarian metastasis (Krukenberg tumor). Following a multidisciplinary team (MDT) evaluation, the patient received five cycles of conversion therapy using the PD-1 inhibitor sintilimab combined with the SOX regimen (S-1 and oxaliplatin), with two cycles of hyperthermic intraperitoneal chemotherapy (HIPEC) administered during these five cycles to manage ascites. After adnexectomy for symptomatic ovarian metastasis, three further cycles of sintilimab, oxaliplatin, and capecitabine were administered before gastrectomy. Results The treatment course was associated with descriptive tumor regression on imaging and declining tumor markers, followed by laparoscopic radical gastrectomy and D2 lymphadenectomy with microscopically negative gastric resection margins. Postoperative histopathology showed residual tumor (ypT1bN0); the overall disease remained M1 because of the previously confirmed ovarian metastasis. During the documented follow-up, no recurrence was identified on the latest CT on January 26, 2026, approximately 29 months after gastrectomy. Conclusion This case suggests that PD-1 inhibition combined with chemotherapy may have contributed to tumor regression and sustained disease control, although its independent contribution cannot be determined.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-19
DOI
https://doi.org/10.3389/fimmu.2026.1895585
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Hepatoid adenocarcinoma of the stomach mimicking primary ovarian cancer: long-term survival following multimodal conversion immunochemotherapy

Hairong Li, Kejian Zou, Longfei Ding, Xionghui He et al.
Frontiers in Immunology
Gastric Cancer Management and Outcomes
article

Case Report: Hepatoid adenocarcinoma of the stomach mimicking primary ovarian cancer: long-term survival following multimodal conversion immunochemotherapy

Hairong Li, Kejian Zou, Longfei Ding, Xionghui He, Xian-Wen Liang, Xianghui Fu
article en

Abstract

Background Hepatoid adenocarcinoma of the stomach (HAS) is a rare, highly aggressive malignancy with no established standardized first-line treatment. Advanced HAS is typically associated with a dismal prognosis. Case presentation We report a 54-year-old female with HAS (cT3N+M1) featuring a primary lesion in the gastric body, massive ascites, and ovarian metastasis (Krukenberg tumor). Following a multidisciplinary team (MDT) evaluation, the patient received five cycles of conversion therapy using the PD-1 inhibitor sintilimab combined with the SOX regimen (S-1 and oxaliplatin), with two cycles of hyperthermic intraperitoneal chemotherapy (HIPEC) administered during these five cycles to manage ascites. After adnexectomy for symptomatic ovarian metastasis, three further cycles of sintilimab, oxaliplatin, and capecitabine were administered before gastrectomy. Results The treatment course was associated with descriptive tumor regression on imaging and declining tumor markers, followed by laparoscopic radical gastrectomy and D2 lymphadenectomy with microscopically negative gastric resection margins. Postoperative histopathology showed residual tumor (ypT1bN0); the overall disease remained M1 because of the previously confirmed ovarian metastasis. During the documented follow-up, no recurrence was identified on the latest CT on January 26, 2026, approximately 29 months after gastrectomy. Conclusion This case suggests that PD-1 inhibition combined with chemotherapy may have contributed to tumor regression and sustained disease control, although its independent contribution cannot be determined.

Frontiers in ImmunologyVol. 17
Hainan General Hospital (CN), Hainan Medical University (CN)
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon